Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arabella Stuart

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
BMJ Open|May 6, 2015
Anti-VEGF therapies in the treatment of choroidal neovascularisation secondary to non-age-related macular degeneration: a systematic reviewArabella Stuart, John A Ford, Susan Duckworth, et al.
BMC Health Services Research|April 13, 2016
A systematic review of strategies to recruit and retain primary care doctorsPuja Verma, John A Ford, Arabella Stuart, et al.
BMC Women'S Health|October 25, 2019
Knowledge and experience of a cohort of HIV-positive and HIV-negative Ghanaian women after undergoing human papillomavirus and cervical cancer screeningArabella Stuart, Dorcas Obiri-Yeboah, Yaw Adu-Sarkodie, et al.
Lancet (London, England)|May 15, 2021
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity dataRobert H Shaw, Arabella Stuart, Melanie Greenland, et al.
Vaccine|July 13, 2025
Development of a live-attenuated vaccine challenge model of Yersinia pestis in humans: Expert consultation on clinical trial considerations, January 2025Anna Rydlova, Emma Smith, Arabella Stuart, et al.
BMJ Global Health|October 20, 2021
Vaccine nationalism and internationalism: perspectives of COVID-19 vaccine trial participants in the United KingdomSamantha Vanderslott, Katherine Emary, Rebecca Te Water Naude, et al.
Science, Technology & Human Values|August 2, 2023
Co-producing Human and Animal Experimental Subjects: Exploring the Views of UK COVID-19 Vaccine Trial Participants on Animal TestingSamantha Vanderslott, Alexandra Palmer, Tonia Thomas, et al.
The Journal of Infection|January 18, 2025
Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort studyShuo Feng, Sagida Bibi, Parvinder K Aley, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
BMJ Open|May 6, 2015
Anti-VEGF therapies in the treatment of choroidal neovascularisation secondary to non-age-related macular degeneration: a systematic reviewArabella Stuart, John A Ford, Susan Duckworth, et al.
BMC Health Services Research|April 13, 2016
A systematic review of strategies to recruit and retain primary care doctorsPuja Verma, John A Ford, Arabella Stuart, et al.
BMC Women'S Health|October 25, 2019
Knowledge and experience of a cohort of HIV-positive and HIV-negative Ghanaian women after undergoing human papillomavirus and cervical cancer screeningArabella Stuart, Dorcas Obiri-Yeboah, Yaw Adu-Sarkodie, et al.
Lancet (London, England)|May 15, 2021
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity dataRobert H Shaw, Arabella Stuart, Melanie Greenland, et al.
Vaccine|July 13, 2025
Development of a live-attenuated vaccine challenge model of Yersinia pestis in humans: Expert consultation on clinical trial considerations, January 2025Anna Rydlova, Emma Smith, Arabella Stuart, et al.
BMJ Global Health|October 20, 2021
Vaccine nationalism and internationalism: perspectives of COVID-19 vaccine trial participants in the United KingdomSamantha Vanderslott, Katherine Emary, Rebecca Te Water Naude, et al.
Science, Technology & Human Values|August 2, 2023
Co-producing Human and Animal Experimental Subjects: Exploring the Views of UK COVID-19 Vaccine Trial Participants on Animal TestingSamantha Vanderslott, Alexandra Palmer, Tonia Thomas, et al.
The Journal of Infection|January 18, 2025
Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort studyShuo Feng, Sagida Bibi, Parvinder K Aley, et al.
Pageof 1